PROCEPT BioRobotics Appoints Elisabeth Sandoval to Board of Directors
26 10월 2021 - 8:00PM
PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical
robotics company focused on advancing patient care by developing
transformative solutions in urology, today announced the
appointment of Elisabeth Sandoval to its Board of Directors.
Ms. Sandoval currently serves as a consultant to the
pharmaceutical industry and is a member of the board of directors
of Intersect ENT, Inc., Satsuma Pharmaceuticals, Inc. and Vyne
Therapeutics, Inc. She is also on the Board of privately held
Alastin Skincare. Ms. Sandoval previously served as the Chief
Commercial Officer and Executive Vice President of Corporate
Strategy at Alder Biopharmaceuticals. She was Chief Commercial
Officer for Kythera Biopharmaceuticals and spent over 20 years at
Allergan in a variety of commercial leadership roles of increasing
responsibility.
“Ms. Sandoval is an accomplished healthcare executive. Her
experience aligns with our current commercial strategies we are
undertaking to accelerate the adoption of Aquablation therapy to
become the standard of care for BPH,” said Reza Zadno, Procept
BioRobotics CEO. "Ms. Sandoval’s well-rounded commercial experience
and success reflects our focus on adding expertise to the board
that will help oversee our rapid growth trajectory.”
"I am pleased to join PROCEPT BioRobotics’ Board of Directors
and be a part of a company dedicated to improving the lives of men
suffering from lower urinary tract symptoms (LUTS) due to BPH. I
strongly believe my experience can help the company achieve their
long-term growth objectives,” said Ms. Sandoval.
With the appointment of Ms. Sandoval, the Board of Directors of
PROCEPT BioRobotics Corporation increased the number of directors
on the Board to nine members.
About PROCEPT BioRobotics CorporationPROCEPT is
a surgical robotics company focused on advancing patient care by
developing transformative solutions in urology. PROCEPT develops,
manufactures and sells the AquaBeam Robotic System, an advanced,
image-guided, surgical robotic system for use in minimally-invasive
urologic surgery with an initial focus on treating benign prostatic
hyperplasia, or BPH. BPH is the most common prostate disease and
impacts approximately 40 million men in the United States. PROCEPT
designed Aquablation therapy to deliver effective, safe and durable
outcomes for males suffering from lower urinary tract symptoms, or
LUTS, due to BPH that are independent of prostate size and shape or
surgeon experience. PROCEPT has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 100 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Investor Contact:Gilmartin GroupMatt Bacso,
CFAMatt.bacso@gilmartinir.com
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024